close
Pharma and Biotech
Menu
close
Pharma and Biotech
close
Pharma and Biotech
Menu
close
Pharma and Biotech
Pharma and Biotech
Menu
close
Cancer remains one of the biggest medical challenges of our time. While many patients benefit from established forms of treatment such as chemotherapy, radiation, or antibody therapies, there are cases in which these treatment options do not achieve the desired results or cause side effects that place an additional heavy burden on severely ill patients. There is also a growing need for personalized solutions that are more precise and enable long-term remission. CAR-T cell therapy is considered one of the most promising approaches in modern oncology.
Conventional cancer treatments typically have a broad impact on the body. Resistance, significant side effects, and insufficient efficacy in certain, particularly aggressive types of blood cancer are well-known challenges. For patients whose disease continues to progress despite chemotherapy or radiation, treatment options dwindle rapidly. This is precisely where CAR-T cell technology comes in, with a highly specific and personalized approach.
CAR-T cell therapies use the patient’s own immune cells and modify them specifically to recognize the malignant cancer cells. In this way, they strengthen the patient’s own immune defense against cancer.
For the treatment, immune cells are first harvested from the patient. These cells are isolated in the laboratory and modified using viral vectors so that they display an artificial receptor (CAR) on their surface. This receptor enables the cells to specifically recognize cancer cells in the body. Following the integration of the viral vector into the cells, the cells are multiplied in special culture vessels outside the patient’s body. Regular analyses monitor their growth and quality. After final processing, the cells are cryopreserved, transported, and later administered to the patient via infusion. There, they exert their effect by actively tracking down and destroying cancer cells, often with remarkable therapeutic success. Since these are the patient’s own cells, they are not rejected.
Clinical successes – particularly in leukemias and lymphomas – show that CAR-T cell therapies can be effective even when all other options have been exhausted. Consequently, oncology is increasingly moving toward personalized treatment strategies.
CAR-T cell therapy offers patients an opportunity that was often unavailable before: A personalized, targeted treatment that, in the best-case scenario, leads to a complete cure.
There is enormous potential for the healthcare system:
CAR-T cell therapies represent a medical milestone. However, the production of CAR-T cells remains a challenge. It is complex, time-sensitive, and, to date, very costly. Their future depends largely on whether this highly complex production process can be carried out efficiently, safely, and reproducibly. Automated systems play a key role in this process. They minimize risks, reduce costs, and enable higher production capacities – all of which are essential prerequisites for reaching more patients.
This is where the OPTIMA ProCell comes in. For the first time, it enables the nearly fully automated, parallel production of multiple CAR-T cell therapies in a Class D cleanroom using integrated isolator technology. Through robot-assisted workflows, precise process monitoring, and flexible configurability, it reduces labor requirements and creates a robust, GMP-compliant production environment. In this way, the OPTIMA ProCell makes a decisive contribution to making CAR-T cell therapies more cost-effective and widely available, bringing personalized cancer treatment one step closer to routine clinical practice.
